May 30th 2024
The COVID-19 pandemic changed medicine forever, and now scientists are forging a new path for healthcare in the future, including in ophthalmology.
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Modern-izing Retina
September 4 - 5, 2024
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Join us after AAO for a CME session | In-Person + Virtual
October 19, 2024
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Study finds differences in pupillary sizes between active, resolved COVID-19 cases
January 7th 2022The investigators believe that, based on their findings, the impact of COVID-19 on the autonomous nervous system warrants further prospective studies and assessment of pupillary function might be a useful test for determining autonomic dysfunction.
Read More
Myocarditis/myopericarditis associated with COVID-19 vaccinations
December 20th 2021A team of Danish investigators have found an increased link between the Moderna vaccination and development of myocarditis or myopericarditis. Meanwhile, the Pfizer vaccination was found to have a significantly increased risk of cardiac adverse effects only among women.
Read More
Regulating blood insulin levels in diabetic patients could lower risk of getting COVID-19
October 29th 2021According to investigators, the SARS-CoV-2 spike protein physically interacts with GRP78 on the cell surface in patients with diabetes and promotes the binding to and accumulation in angiotensin-converting enzyme 2 (ACE2)-expressing cells.
Read More
Coronavirus induces macrophage-mediated cytokine storm in diabetic patients
October 27th 2021A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.
Read More
Retinal, choroidal microvascular lesions may be linked to severe COVID-19 infections
October 25th 2021According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.
Read More
Merck seeking FDA emergency use authorization for oral COVID-19 treatment
October 11th 2021Merck and Ridgeback Biotherapeutics are seeking emergency use authorization for molnupiravir, an oral experimental antiviral treatment for mild-to-moderate COVID-19 in adults at risk for virus progression or hospitalization.
Read More